Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03198494 · ClinicalTrials.gov registry record · NA
Acoustic Stimulation for Seizure Suppression
A NA study of Epilepsy, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT03198494: Active NA study of Epilepsy, sponsored by NYU Langone Health.
NCT03198494 is a NA study of Epilepsy that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 36 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03198494, a NA study of Epilepsy, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to test the feasibility and physiological effect of low-frequency (1 Hz) acoustic stimulation delivered during nocturnal NREM sleep in epilepsy patients. The long-term goal is to develop this protocol for daily, long-term use in a home setting, for nocturnal seizure and IED suppression
Primary Outcome
Assessment of how well participants learn to use stimulation smart-phone application and headphones, defined as the percentage of subjects with correctly maintained earphones during the first four hours of nocturnal sleep in the first days of use.
Conditions Studied
Interventions
- OTHER Acoustic 1Hz Stimulation
- OTHER Sham Background Noise
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-08-17 |
| Est. Completion | 2028-11-21 |
| Phase | NA |
What the registry record for NCT03198494 still lists
NCT03198494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Acoustic 1Hz Stimulation is the first listed.
NCT03198494 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03198494 about?
NCT03198494 is a clinical study titled "Acoustic Stimulation for Seizure Suppression". The objective of this study is to test the feasibility and physiological effect of low-frequency (1 Hz) acoustic stimulation delivered during nocturnal NREM sleep in epilepsy patients. The long-term goal is to develop this protocol for daily, long-term use in a home setting, for nocturnal seizure an...
What is the current status of trial NCT03198494?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2017-08-17. Estimated completion is 2028-11-21.
What conditions does trial NCT03198494 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT03198494?
The interventions under investigation include: Acoustic 1Hz Stimulation (OTHER), Sham Background Noise (OTHER).
Who is sponsoring clinical trial NCT03198494?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03198494 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03198494's enrollment target sits among peer trials
36 105th of 160 higher than 56 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SeizEAR Safety Study
RECRUITING · NA
-
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
RECRUITING · NA
-
Subcortical Arousal in Perceptual Awareness
RECRUITING · NA
-
Prediction of Anxiety and Memory State
RECRUITING · NA
-
Implementation and Cost Evaluation of Project UPLIFT
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI